Benefit of early discharge among patients with low-risk pulmonary embolism

PLoS One. 2017 Oct 10;12(10):e0185022. doi: 10.1371/journal.pone.0185022. eCollection 2017.

Abstract

Clinical guidelines recommend early discharge of patients with low-risk pulmonary embolism (LRPE). This study measured the overall impact of early discharge of LRPE patients on clinical outcomes and costs in the Veterans Health Administration population. Adult patients with ≥1 inpatient diagnosis for pulmonary embolism (PE) (index date) between 10/2011-06/2015, continuous enrollment for ≥12 months pre- and 3 months post-index date were included. PE risk stratification was performed using the simplified Pulmonary Embolism Stratification Index. Propensity score matching (PSM) was used to compare 90-day adverse PE events (APEs) [recurrent venous thromboembolism, major bleed and death], hospital-acquired complications (HACs), healthcare utilization, and costs among short (≤2 days) versus long length of stay (LOS). Net clinical benefit was defined as 1 minus the combined rate of APE and HAC. Among 6,746 PE patients, 95.4% were men, 22.0% were African American, and 1,918 had LRPE. Among LRPE patients, only 688 had a short LOS. After 1:1 PSM, there were no differences in APE, but short LOS had fewer HAC (1.5% vs 13.3%, 95% CI: 3.77-19.94) and bacterial pneumonias (5.9% vs 11.7%, 95% CI: 1.24-3.23), resulting in better net clinical benefit (86.9% vs 78.3%, 95% CI: 0.84-0.96). Among long LOS patients, HACs (52) exceeded APEs (14 recurrent DVT, 5 bleeds). Short LOS incurred lower inpatient ($2,164 vs $5,100, 95% CI: $646.8-$5225.0) and total costs ($9,056 vs $12,544, 95% CI: $636.6-$6337.7). LRPE patients with short LOS had better net clinical outcomes at lower costs than matched LRPE patients with long LOS.

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use
  • Black or African American
  • Costs and Cost Analysis / economics*
  • Female
  • Hospitalization / economics*
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Patient Discharge
  • Pulmonary Embolism / drug therapy
  • Pulmonary Embolism / economics
  • Pulmonary Embolism / epidemiology*
  • Pulmonary Embolism / pathology
  • Risk Factors
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / economics
  • Venous Thromboembolism / epidemiology*
  • Venous Thromboembolism / pathology
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin

Grants and funding

This study was funded by Janssen Scientific Affairs, LLC.